SQUAWK/NEWS
Account
Account
Menu
Live News EQUITY ARTICLE L impact

Citizens Reiterates Market Outperform on Abivax, Maintains $187 Price Target

Citizens analyst Jason N. Butler reiterates Abivax (NASDAQ: ABVX ) with a Market Outperform and maintains $187 price target.

ABVX

Citizens analyst Jason N.

Butler reiterates Abivax (NASDAQ: ABVX ) with a Market Outperform and maintains $187 price target.